http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2610408-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fe216aafd92230af08bea3ad94a69638 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-542 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-487 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-487 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-542 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate | 2016-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28dd5d762cb452ee30e0251fa1eefd68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64bc0323ad0286511295e7e8379e0a4d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9b07b7de18e9c3d5964c892f59770d7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7374d3892d32826318f13028d59ef77f |
| publicationDate | 2017-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2610408-C1 |
| titleOfInvention | Method for treatment of acute bacterial postoperative endophthalmitis |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine, in particular to ophthalmology, and is intended for treatment of acute bacterial postoperative endophthalmitis. Method includes removal of vitreous cavity content by subtotal vitrectomy with simultaneous replacement of vitreous with BSS solution, sampling content of vitreous cavity and anterior eye chamber for microflora inoculation, determination of sensitivity to antibiotics and the following intravitreal introduction of two antibacterial preparations: 1 mg/0.1 ml of vancomycin and 2.0-2.25 mg/0.1 ml of ceftazidim. First antibiotic to be introduced into vitreous cavity is vancomycin in dose 1 mg/0.1 ml. After that, content with diluted vancomycin in volume 0.2 ml is sampled from vitreous cavity. Then ceftazidim is introduced in dose 2.0-2.25 mg/0.1 ml. Taken sample with vancomycin is directed to spectrophotometry in ultraviolet part of spectrum with wavelength 280 nm to determine concentration of vancomycin in vitreous cavity. If concentration value is 130 mcg/ml and higher, it is concluded that concentration of antibiotic is sufficient for elimination of bacterial flora. If concentration value is lower than 130 mcg/ml, it is concluded that concentration of antibiotic is insufficient and introduction of 1mcg/0.1 ml of vancomycim and 2.0-2.25 mg/0.1 ml of ceftazidim into vitreous cavity is repeated on the following day. From the following day after vitrectomy until results of bacteriological inoculation are received, 25 mg/0.25 ml and 100 mg/0.5 ml of ceftazidim are introduced 2 times per day into subconjunctival space. After receiving the results of bacteriological inoculation on 2-3 day, the antibiotic that possesses activity with respect to identified pathological agent, is continued to be used for postoperative subconjunctival introduction. n EFFECT: method ensures elimination of infectious process in eye, preservation of eye structures and maximal preservation of visual eye functions. n 2 dwg, 1 tbl, 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2699506-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2655801-C1 |
| priorityDate | 2016-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.